New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.

Fluticasone furoate/umeclidinium bromide/vilanterol dry powder inhaler (Trelegy Ellipta®) is a fixed-dose triple combination of a corticosteroid (ICS), a long-acting anti-muscarinic (LAMA)  and a long-acting beta-agonist (LABA) for relief of symptoms in adults with chronic obstructive pulmonary disease.

This review is older than 3 years and has been archived. To request a copy, contact nuth.nyrdtc.rxsupp@nhs.net.

NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 30th of June 2024.
For more information visit www.nice.org/accreditation